Management of SGLT-2 Inhibitors in the Perioperative Period: Withhold or Continue?
British Journal of Hospital Medicine · 2025
DOI: 10.12968/hmed.2024.0611 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift British Journal of Hospital Medicine, 2025. Verfasst von Zack Pittack. Beteiligte Einrichtung: Department of Anaesthesia, Northumbria Healthcare NHS Foundation Trust, Newcastle-Upon-Tyne, UK. Hauptthemen laut MEDLINE: Sodium-Glucose Transporter 2 Inhibitors, Diabetes Mellitus, Type 2, Perioperative Care, Hypoglycemic Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 6 Literaturangaben.
Abstract (Originalsprache)
Sodium-glucose cotransporter 2 (SGLT-2) inhibitors are commonly prescribed in diabetes mellitus and increasingly for cardiorenal protection. They carry the risk of euglycaemic diabetic ketoacidosis (eDKA). Guidelines around the perioperative handling of these medications are limited and some evidence suggests that withholding them can lead to more surgical complications and poorer glycaemic control. This article gives an overview of arguments for and against withholding SGLT-2 inhibitors in the perioperative period.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Anaesthesia, Northumbria Healthcare NHS Foundation Trust, Newcastle-Upon-Tyne, UK.
Zitieren
APA
Pittack, Z. (2025). Management of SGLT-2 Inhibitors in the Perioperative Period: Withhold or Continue?. British Journal of Hospital Medicine. https://doi.org/10.12968/hmed.2024.0611
Vancouver
Pittack Z. Management of SGLT-2 Inhibitors in the Perioperative Period: Withhold or Continue?. British Journal of Hospital Medicine. 2025. doi:10.12968/hmed.2024.0611
BibTeX
@article{Pittack2025,
author = {Pittack, Zack},
title = {Management of SGLT-2 Inhibitors in the Perioperative Period: Withhold or Continue?},
journal = {British Journal of Hospital Medicine},
year = {2025},
doi = {10.12968/hmed.2024.0611}
}
EUVIMED